These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
150 related items for PubMed ID: 8607901
1. The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Nickerson-Nutter CL, Medvedeff ED. Arthritis Rheum; 1996 Mar; 39(3):515-21. PubMed ID: 8607901 [Abstract] [Full Text] [Related]
2. Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis. Anderson GD, Keys KL, De Ciechi PA, Masferrer JL. Inflamm Res; 2009 Feb; 58(2):109-17. PubMed ID: 19184362 [Abstract] [Full Text] [Related]
3. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase. McMillan RM, Spruce KE, Crawley GC, Walker ER, Foster SJ. Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748 [Abstract] [Full Text] [Related]
5. Antiedematous effects of combination therapies with the leukotriene synthesis inhibitor BAY X 1005 in the archidonic acid-induced mouse ear inflammation test. Burchardt ER, Müller-Peddinghaus R. Prostaglandins Leukot Essent Fatty Acids; 1997 Apr; 56(4):301-6. PubMed ID: 9150376 [Abstract] [Full Text] [Related]
7. Potential anti-inflammatory effects of 5-lipoxygenase inhibition--exemplified by the leukotriene synthesis inhibitor BAY X 1005. Müller-Peddinghaus R. J Physiol Pharmacol; 1997 Dec; 48(4):529-36. PubMed ID: 9444606 [Abstract] [Full Text] [Related]
12. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. Rao NL, Dunford PJ, Xue X, Jiang X, Lundeen KA, Coles F, Riley JP, Williams KN, Grice CA, Edwards JP, Karlsson L, Fourie AM. J Pharmacol Exp Ther; 2007 Jun; 321(3):1154-60. PubMed ID: 17371808 [Abstract] [Full Text] [Related]
13. A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors. Zweifel BS, Hardy MM, Anderson GD, Dufield DR, Pufahl RA, Masferrer JL. Eur J Pharmacol; 2008 Apr 14; 584(1):166-74. PubMed ID: 18295198 [Abstract] [Full Text] [Related]
16. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Fruchtmann R, Mohrs KH, Hatzelmann A, Raddatz S, Fugmann B, Junge B, Horstmann H, Müller-Peddinghaus R. Agents Actions; 1993 Mar 14; 38(3-4):188-95. PubMed ID: 8213345 [Abstract] [Full Text] [Related]